🧬 HMA + Venetoclax in Younger AML — 50 Pearls (2026 Meta-analysis) 📌 Credits: Perrone et al., Cancer 2026 ⸻ 🔥 Paradigm shift: VEN+HMA moving beyond “unfit” → selected younger AML 🧬 Mechanism: BCL-2 inhibition → restores apoptosis → deep responses 👨‍⚕️ Population: Median age ~54 yrs (<70 included) 📊 Total data: 8 studies | 429 pts (RCT + phase 2 + real-world) 🎯 CR/CRi pooled: 66% 🧪 MRD negativity: ~69% → deep remission signal 📈 1-year OS: ~75% → > historical (~62%) 📉 1-year EFS: ~59% (low heterogeneity) 🧠 Key: EFS consistency strongest signal across studies 🔁 Bridge to transplant: ~66% proceed to HSCT 🧬 Decitabine trend > azacitidine (EFS/OS signal) ⚖️ Compared to IC: similar or better early outcomes in selected pts 🚫 Not replacing IC in favorable-risk AML ⚠️ More promising in adverse-risk AML 🧬 MRD-driven strategy emerging 🔄 Potential chemo-sparing induction approach 🏥 Less toxicity vs IC → fewer infections, cytopenias 📉 Lower hospitalization burden (outpatient feasible) 🧠 QoL advantage (less ICU, less long stays) 💰 Likely cost-effective (data extrapolated) 📊 CR heterogeneity high (I² ~89%) 🧪 MRD variability due to methods/timing 📉 OS heterogeneity low → robust outcome 🧬 Biology-driven response (TP53, FLT3, NPM1 matter) 🧪 ELN 2024 integrates VEN-based approaches ⚠️ Fitness > age → key selection principle 🧬 Favorable-risk AML → IC still gold standard ⚠️ PARADIGM excluded key subtypes → limits generalizability 🧬 Hybrid strategies (VEN+HMA → IC consolidation) used 🔁 Continuous therapy needed if no HSCT 🧠 MRD-negative pts → may defer transplant (investigational) 📉 Relapse-free survival data inconsistent 🧬 Younger pts (≤45 yrs) → better EFS 📊 CR range wide: ~40%–89% across studies 📉 US real-world outcomes lower vs trials 🌍 Geography variation (China vs US vs EU cohorts) 🧪 Venetoclax duration impact unclear ⚠️ Dosing heterogeneity across studies 🧬 Transplant intent differs across trials 📊 HSCT rates vary widely (33%–100%) 🧠 Suggests strategy tailoring (not uniform) 🧬 VEN+FLAG-IDA / VEN+IC also emerging competitors 📉 Toxicity still present (cytopenias, infections) 🧪 Need standardized MRD assessment 📊 No strong randomized superiority vs IC yet 🧬 Strong rationale for phase 3 trials 🧠 Key concept: induction ≠ necessarily intensive chemo 🔬 VEN+HMA = “biologic induction” approach 📌 Best role: bridge-to-transplant strategy ⚠️ Patient selection remains critical 🧬 Future: biomarker-driven allocation 📊 Meta-analysis limitation: heterogeneity + mixed designs 🧠 Clinical takeaway: powerful option in non-favorable risk younger AML ⸻ #AML #Venetoclax #HMA #Leukemia #BMT #Transplant #Hematology #Oncology